DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous neoplasm with negative cytology by Simpson, Rachel E. et al.
DNA Profile Components Predict Malignant Outcomes in Select Cases of 
Intraductal Papillary Mucinous Neoplasm with Negative Cytology 
Rachel E. Simpson MDa, Nathan J. Cockerill MDa, Michele T. Yip-Schneider PhDa,b, Eugene P. Ceppa 
MDa,b, Michael G. House MDa, Nicholas J. Zyromski MDa, Attila Nakeeb MDa, Mohammad A. Al-Haddad 
MDb,c, C. Max Schmidt MD/MBA/PhDa,b,d-f 
a Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 
b Indiana University Health Pancreatic Cyst and Cancer Early Detection Center, Indianapolis, IN 
c Department of Medicine, Division of Gastroenterology, Indiana University Hospital, Indianapolis  
d Indiana University Simon Cancer Center, Indianapolis, IN  
e Walther Oncology Center, Indianapolis, IN 
f Department of Biochemistry/Molecular Biology, Indiana University School of Medicine, Indianapolis, 
IN  
Correspondence Address: 
C. Max Schmidt, MD, PhD, MBA
Department of Surgery 
Indiana University School of Medicine 
545 Barnhill Drive, Emerson Hall 129 
Indianapolis, IN  46202  
Phone: (317) 948-8358 Email:  maxschmi@iupui.edu 
Presentation: 
Selected for Oral Presentation at the Central Surgical Association annual meeting 
Columbus, OH  3/15/18-3/17/18 
Financial Support: 
No external financial support or grant funding was used in this research study 
Conflict of Interest (All Authors): 
None 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Simpson, R. E., Cockerill, N. J., Yip-Schneider, M. T., Ceppa, E. P., House, M. G., Zyromski, N. J., ... & Schmidt, C. 
M. (2018). DNA profile components predict malignant outcomes in select cases of intraductal papillary mucinous 
neoplasm with negative cytology. Surgery, 164(4), 712-718. https://doi.org/10.1016/j.surg.2018.05.033
ABSTRACT 
Background: Predicting malignancy in intraductal papillary mucinous neoplasm (IPMN) 
remains challenging. Integrated molecular pathology combines pancreatic fluid DNA and 
clinical factors into a malignant potential score. We sought to determine the utility of DNA 
components alone in predicting HGD/Invasive disease. 
Methods: We retrospectively reviewed records from 1106 patients with IPMN. We excluded 
non-IPMN cases, and cases with definitive malignant cytology. A total 225 patients had 283 
DNA profiles (98 followed by surgery, 185 followed by ≥23 month surveillance). HGD/Invasive 
outcomes were HGD, IPMN-invasive, and adenocarcinoma on surgical pathology or 
mesenteric/vascular invasion, metastases or biopsy with HGD or adenocarcinoma during 
surveillance. 
Results: High Quantity DNA predicted (P=0.004) HGD/Invasive outcomes with sensitivity of 
78.3%, but 52.7% specificity, indicating benign cases may exhibit High Quantity DNA. High 
clonality loss of heterozygosity (HC LOH) of tumor suppressor genes was 98.0% specific, 
strongly predicting HGD/Invasive disease, but lacked sensitivity (20.0%.) High Quantity DNA + 
HC LOH had 99.0% specificity for HGD/Invasive disease. KRAS mutation alone did not predict 
HGD/Invasive disease, but combined with High Quantity DNA (specificity 84.7%) and HC LOH 
(specificity 99.0%) strongly predicted HGD/Invasive outcomes. 
Conclusion: Certain DNA components are highly specific for HGD/Invasive disease and may 
indicate aggressive lesions requiring resection when cytology fails. 
 
 
Abbreviations: 
Carcinoembryonic Antigen (CEA) 
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Intraductal Papillary Mucinous Neoplasm (IPMN) 
Loss of Heterozygosity (LOH) 
Negative Predictive Value (NPV) 
Positive Predictive Value (PPV) 
Worrisome Features (WF) 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 Intraductal papillary mucinous neoplasms (IPMN) are one of the few known premalignant 
lesions of the pancreas, and have been diagnosed with increasing frequency. When first described 
in the 1980’s by Ohashi et al., IPMN were felt to be incredibly rare.1 However, others have 
concluded IPMN to be one of the most common pancreatic cystic neoplasm, representing 24% of 
cysts resected at a single institution.2 Thus, the tremendous effort dedicated to understanding 
IPMN over the preceding decades has been warranted. 
 IPMN may transform through progressive grades of dysplasia, from low, moderate, high-
grade (HGD), to invasive IPMN. Current 2012 International Consensus Guidelines (ICG) focus 
on clinical and radiographic criteria to predict the most aggressive lesions necessitating resection 
depending on the presence of High-Risk Stigmata (HRS) or Worrisome Features (WF).3 These 
consensus guidelines have been noted to provide reasonable sensitivity (72-90%) but often poor 
specificity (46-78%) for detecting HGD or invasive IPMN.4, 5 For this reason, research dedicated 
to understanding IPMN at a molecular level has gained favor. 
 Since the mid-2000’s, PancraGEN from Interpace Diagnostics (previously Redpath) has 
sought to predict which pancreatic cysts held the highest potential for malignancy. Pancreatic cyst 
or ductal fluid gathered via endoscopy is analyzed for level and quality of DNA, oncogene 
mutations and loss of heterozygosity (LOH) of tumor suppressor genes. Clinical data (cyst size, 
main pancreatic duct diameter, cyst fluid Carcinoembryonic Antigen (CEA) level) is combined 
with these DNA factors to develop an aggregate malignancy risk score. This testing process is 
termed Integrated Molecular Pathology (IMP).6 However, this integration process makes it 
difficult to determine the merits of the DNA components alone.   
 Prior studies have sought to determine if DNA features could predict mucinous 
differentiation as well as malignancy. Several studies have proposed High Quantity and/or High 
Quality DNA on pancreatic cyst fluid analysis as a predictor of a non-benign or malignant course 
of pancreatic cysts.7-11 Mutations of the KRAS oncogene have been studied extensively, and are 
commonly discovered in pancreatic and other cancers;12 but results of prior studies regarding the 
ability to predict a malignant outcome for pancreatic cysts are conflicting.8, 10-15 The presence of 
KRAS or GNAS mutations have been determined to be specific for mucinous differentiation of 
pancreatic cysts,8, 12, 15-17 with GNAS especially specific for IPMN.18, 19 Allelic LOH of tumor 
suppressor genes has also been associated with mucinous differentiation or malignant pathology,17, 
20 especially when in combination with KRAS mutations.7-11, 13, 21 
 Studies dedicated to IPMN, especially the surveillance population, are lacking, making the 
application of prior findings to this specific population unclear. Our study focuses on the predictive 
capabilities of each DNA component for patients with IPMN specifically, including both surgical 
and surveillance cohorts. 
METHODS 
Patient Selection: A prospectively maintained database of patients with IPMN (n=1106) from 
Indiana University was retrospectively reviewed. We queried for patients with non-malignant 
cytology (no definitive HGD or carcinoma) on endoscopic ultrasound guided fine-needle 
aspiration (EUS-FNA) of cyst/duct fluid that had subsequent IMP testing performed. 283 IMP 
cases (225 patients) were examined: 98 cases were followed by surgery whereas 185 were followed 
by a minimum of 23 months surveillance. The surgical cohort was defined by IPMN on surgical 
pathology specimens corresponding to the anatomic location of cyst fluid analysis. Inclusion in 
the surveillance cohort required convincing evidence of IPMN, i.e., multifocal pancreatic cysts; 
solitary pancreatic cysts with a connection to the main pancreatic duct or main duct dilation with 
cytology suggestive of IPMN, cyst fluid mucin, CEA > 192ng/mL or GNAS mutation.  
A HGD/invasive outcome included HGD/invasive IPMN or adenocarcinoma on surgical 
pathology; malignant cytology on subsequent biopsy; and radiographic/endoscopic evidence of 
invasive mass lesion or metastatic disease during surveillance.  
At our institution, patients diagnosed with pancreatic cysts >1cm or main duct dilation not 
clearly representative of IPMN typically undergo initial EUS-FNA with DNA profiling to establish 
a baseline diagnosis based on endoscopic appearance, fluid and cytology characteristics, and 
molecular profile. Patients undergoing surveillance are recommended for subsequent testing every 
3 or 5 years based on stratification to a high- or low-risk protocol respectively. A total 200µL of 
fluid are optimal for testing, and coverage varies by insurance. 
Clinically, patients were selected for surgery or surveillance primarily based on the 
presence/absence of symptoms, general health and surgical candidacy, progression of disease, 
cytology, and ICG criteria. As the role of DNA profiling is not entirely clear for the IPMN 
population, this data was not used independently to recommend a management strategy. 
Integrated Molecular Pathology Molecular Parameters: In our study, patients with any value 
besides Low Quantity DNA (range Low-Greatly Elevated) were considered to have “High 
Quantity” DNA. Similarly, patients with all but Poor Quality DNA (range Poor-Good) were 
designated to the “High Quality” DNA group. “High Risk” DNA designation requires both High 
Quantity and High Quality DNA. Oncogene mutations (KRAS and GNAS) and allelic LOH are 
also reported.22 These are considered High Clonality (HC) when ≥75% of the DNA is affected.23  
Statistical Analysis: The sensitivity, specificity, accuracy, positive predictive value (PPV), 
negative predictive value (NPV) and positive likelihood ratios (LR+) were calculated. Chi-square 
analysis/Fisher’s Exact test were used to determine significant associations (α-level of 0.05.) IBM 
SPSS software, version 24 was used for these analyses. 
RESULTS 
Surgery and Surveillance Cohorts: Benign vs. HGD/Invasive: Of the 283 IMP cases (225 patients), 
98 were followed by pancreatectomy, while the remaining 185 were followed by a minimum of 
23 months surveillance. Twenty-three IMP cases were associated with a HGD/Invasive outcome 
determined by surgical pathology, with a median time to diagnosis of 5.2 months after IMP.  The 
other 260 cases had a benign outcome, concluded by surgical pathology or surveillance at a median 
3.6 months and 47.3 months after IMP respectively. (Table 1) 
 The most sensitive predictor of HGD/Invasive outcome was the presence of High Quantity 
DNA (sensitivity 78.3%, P=0.004). However, High Quantity DNA alone was poorly specific 
(52.7%), and not an accurate (54.8%) predictor of HGD/Invasive disease, with low PPV (12.8%). 
Thus, most HGD/Invasive lesions exhibit High Quantity DNA, but many benign lesions exhibit 
this feature as well. The single most specific DNA factor for HGD/Invasive disease was the 
presence of HC LOH (specificity 98.0%, P=0.003). Alone, HC LOH had PPV of 50%, but occurred 
proportionally much more frequently in the HGD/Invasive group with a LR+ of 10. The 
combination of High Quantity DNA and HC LOH (P=0.006) provided even greater specificity 
(99.0%), accuracy (91.4%), PPV (60%), and LR+ (15). An LR+ of this value provides a post-test 
probability of HGD/Invasive disease tremendously greater than the pre-test probability, and 
strongly suggests the possibility of more aggressive disease. The combination of High Quality 
DNA or High Risk DNA and HC LOH provided 100% specificity, >90% accuracy, and a PPV of 
100% (P<0.05). HC LOH in addition to a HC KRAS mutation was associated with HGD/Invasive 
outcomes (P=0.011), with a specificity of 98.5% and accuracy of 90.9%.  The presence of both 
KRAS and GNAS mutations, in addition to elevated Quantity and/or Quality of DNA was 
significantly associated with HGD/Invasive disease (P=0.032) with moderate sensitivity (66.7%), 
high specificity (95.2%) and accuracy (91.7%), and reasonable PPV (66.7%). DNA components 
reaching/approaching significant associations with HGD/Invasive disease are summarized in 
Table 2.  
 Several other DNA components, alone and in combination, revealed high specificity for 
HGD/Invasive outcomes, but statistical or near-statistical significance on Chi-square analysis was 
not reached.  These are shown in Supplemental Table 1s (for the online version). 
Surgery Cohort Alone: Benign vs. HGD/Invasive: 98 IMP cases were followed by surgery, with a 
resulting 23 HGD/Invasive and 75 benign outcomes. High Quantity DNA (P=0.019) again was the 
most sensitive (78.3%) in determining HGD/Invasive disease; however, specificity (49.3%), 
accuracy (56.1%), and PPV (32.1%) were overall poor. High Quality DNA (P=0.019) and High 
Risk DNA (P=0.015) were less sensitive (47.8% and 43.5%), but more specific (77.3% and 
81.3%), with greater accuracy (70.4% and 72.4%) and slightly improved PPV (39.3% and 41.7%) 
for HGD/Invasive lesions. The combination of High Quality DNA with HC LOH (P=0.017) 
provided the greatest specificity (100.0%), accuracy (77.3%) and PPV (100%). However, this 
combination occurs rarely, thus lacked sensitivity (15.0%). In contrast to the surgery + surveillance 
cohort, HC LOH alone fell short of statistical significance (P=0.077), but continued to show high 
specificity (94.5%) and accuracy (74.7%) for HGD/Invasive outcomes, with a PPV of 57.1%. HC 
LOH in combination with High Risk DNA provided even greater specificity (100.0%), accuracy 
(76.0%), and PPV (100%), but did not reveal a significant relationship with HGD/Invasive 
outcomes (P=0.068). Any degree of elevated DNA (High Quantity +/- High Quality) in addition 
to both KRAS and GNAS mutation most closely approximated a statistically significant 
relationship with HGD/Invasive disease (P=0.056), with fair sensitivity (66.7%), good specificity 
(93.3%), moderate PPV (66.7%), and the highest accuracy of any combination (88.9%). 
Furthermore, this combination of DNA components provided the highest LR+ of 10, which greatly 
increases the post-test probability of HGD/Invasive disease when present. (Table 3).  
Several other DNA components and combinations showed high specificity for 
HGD/Invasive disease, but no statistically significant relationship. These are outlined in 
Supplemental Table 2s (for the online version).   
Outcome Predictions Based on 2012 Consensus Guidelines Criteria: When considering all HRS, 
WF (excluding pancreatitis), and EUS findings, patients recommended for surgery based on ICG 
(ICG+, n=44) had a rate of HGD/Invasive disease of 29.5%. When patients from the ICG+ group 
with HRS were excluded to include only patients with WF, or more “borderline” lesions, (WF+, 
n=111), the rate of HGD/Invasive disease was 9.9%. Finally, patients lacking HRS or WF (ICG-, 
n=158) had the lowest rate of HGD/Invasive disease at 1.9%. Separate analyses were performed 
on these strata. In ICG+ or WF+ cases, HC LOH was significantly associated with HGD/Invasive 
disease (P<0.05), with high specificity (>98.0%) and moderate accuracy (>77%), with PPV of 
100% (ICG+) and 66.7% (WF+). HC LOH plus High Quality DNA (P=0.120) or HC KRAS 
(P=0.013) mutation in the WF+ group provided 100% specificity and 100% PPV. The ICG- group 
revealed no statistically significant relationships. The most compelling DNA feature was High 
Quantity DNA (P=0.118), with great sensitivity (100%), but poor specificity (51.6%) and accuracy 
(52.5%). Though the PPV of this DNA feature was poor (3.9%), the NPV reached 100%. These 
and other DNA analyses are summarized in Table 4. 
 
 
DISCUSSION 
 IPMN are known to harbor malignant potential, but differentiating between low and higher 
risk lesions is difficult. In the era of individualized medicine, it is no surprise that the genetic 
profile of these cysts will be increasingly incorporated into clinical decision-making. Prior studies 
have described the utility of cyst fluid DNA in predicting mucinous differentiation or malignancy 
of pancreatic cysts in general. To our knowledge, the present study is the largest evaluation of the 
value of the DNA components for the IPMN-specific surgical and surveillance population. 
 We found the most sensitive determinant of a HGD/Invasive outcome was the presence of 
High Quantity DNA (78.3%). This finding is mechanistically plausible, as the development of 
cancer relies on the unregulated, disorganized growth and proliferation of cells.24 However, as 
Khalid et al. describes, certain benign processes, such as inflammation or necrosis, may lead to 
the release of cellular DNA.9  This may explain why, though highly sensitive, High Quantity DNA 
is poorly specific for HGD/Invasive disease in our surgical +/- surveillance analyses. High Quality 
DNA was a predictor of HGD/Invasive disease in the surgery alone group, with greater specificity 
(>75%). DNA may degrade over time in a stagnant cyst or in the presence of a benign 
inflammatory process. Therefore, in the presence of rapid proliferation and absence of benign 
inflammatory disease, the presence of High Quality DNA may suggest a malignant processes.  
 Most prior studies examining the role of KRAS mutation in predicting HGD/Invasive 
pathology in all pancreatic cyst types have revealed no significant association.8, 10, 12 In the present 
study, we validate these prior findings in our IPMN-specific population, as we found no significant 
relationship between KRAS mutation and HGD/Invasive outcomes in our surgery +/- surveillance 
analyses. KRAS mutation only revealed predictive potential for HGD/Invasive disease in the 
presence of concomitant mutations or elevated Quantity or Quality of DNA. 
 The presence of HC LOH was the most consistent predictor of HGD/Invasive outcomes in 
the present study. HC LOH alone was highly specific for HGD/Invasive IPMN (98.0%) in our 
analysis of surgery + surveillance patients. However, when surgical patients were examined alone, 
though still highly specific, the association only approached statistical significance. Schoedel et 
al. and Khalid et al. have previously shown an association between KRAS mutations + LOH and 
HGD/Invasive outcomes.10, 21 Similarly, we demonstrated a significant association between HC 
LOH + KRAS mutation and HGD/Invasive outcomes in our surgery + surveillance analysis. In our 
surgical cohort, the combination of HC LOH and High Quality DNA provided 100% specificity 
for HGD/Invasive outcomes. To our knowledge this has not been documented prior in the 
literature. 
In our subgroub analysis of ICG+, WF+, and ICG- patients, we found that the ability of 
DNA features to predict HGD/Invasive disease varied, likely owed to differing prevalence of 
HGD/Invasive outcomes in these strata. In practice, patients that are ICG+ are frequently 
recommended for surgery. However, not all individuals are amenable or optimal surgical 
candidates. In the ICG+ and WF+ subgroups, HC LOH again was highly specific for 
HGD/Invasive disease, with or without the presence of High Quality DNA or KRAS mutation, 
with a PPV 66.7-100%. Therefore, the presence of HC LOH in patients that are ICG+ but not 
optimal surgical candidates, or have more borderline lesions (WF+) should alert the clinical to a 
greater likelihood of HGD/Invasive disease. For those lacking any HRS or WF (ICG-), the 
presence of High Quantity DNA provided 100% sensitivity with a NPV of 100%. Thus, the 
absence of High Quantity DNA only occurred in benign cases. Though this did not reach statistical 
significance, one may consider the absence of High Quantity DNA to support ongoing or 
potentially relaxed surveillance over surgery in this group. As the numbers in these subgroups 
were small, future studies are needed to validate these findings. 
 This study includes a specific subgroup of patients with IPMN who have undergone EUS-
FNA with resulting non-malignant cytology and subsequent IMP testing. Cytology historically has 
shown high specificity but low sensitivity (65%) for detecting malignant IPMN.25 Our data in 
combination with prior studies demonstrates that DNA profiling may be useful in capturing more 
HGD/Invasive IPMN when the gold standard of cytology fails. 
 Our study had several potential limitations. The number of HGD/Invasive cases is 
relatively small. This is in part due to the exclusion of patients with preoperative cytology or core 
biopsy revealing high grade atypia or adenocarcinoma for whom DNA profiling is not performed, 
as it would not enhance clinical decision making. Thus, blatantly malignant or aggressive lesions 
on imaging or by EUS-FNA cytology tend to either immediately undergo surgery or are self-
selected out of the IMP testing process. Because of this, the power of our study may be limited. 
Molecular pathology and surveillance outcome data was gathered retrospectively to supplement 
our prospectively maintained IPMN database. It is plausible that a fraction of our surveillance 
cohort may contain non-IPMN cystic lesions. While surgical pathology, cytology, or biopsy would 
ideally serve as the gold standard for diagnosis, patients without these diagnostic tests have less-
definitive outcomes. We attempted to minimize the potential for misallocation to our benign vs 
HGD/Invasive groups through exclusion of patients with insufficient duration of follow-up (<23 
months) and imaging surveillance (radiographic or endoscopic) available at this 23 month point. 
Finally, the number of patients with specific DNA parameters is oftentimes small, and should be 
interpreted cautiously.   
 The present study is unique in a number of ways. We performed the largest evaluation of 
cyst fluid DNA components on an IPMN-specific population to date. This helps to provide internal 
validity for the application of these DNA parameters to IPMN specifically, rather than pancreatic 
cysts in general. Most prior studies exclude surveillance patients; the inclusion of non-surgical 
patients in our study we feel is more representative of the true IPMN population. However, surgical 
pathology provides the most definitive means of determining a HGD/Invasive or benign outcome. 
Therefore, the DNA measures with the strongest predictive power are likely to be reflected in the 
surgery population.     
 We proposed several DNA profiles that may aid the clinician in decision making, 
especially in cases of non-diagnostic cytology. The majority of HGD/Invasive IPMN exhibit High 
Quantity of DNA, and can be considered the best candidate for a “screen” for this more advanced 
disease. However, this feature is nonspecific, as many benign cysts also exhibit elevated levels of 
DNA. HC LOH alone and in combination with other DNA factors is most consistently associated 
with HGD/Invasive outcomes with a high degree of specificity, and should alert the physician to a 
higher probability of aggressive disease requiring resection.  KRAS mutations only predicted 
HGD/Invasive IPMN when combined with other DNA factors. Thus, the predictive role of KRAS 
mutation is less clear. Molecular profiling of pancreatic cyst fluid should not be used as a stand-
alone test, but can be useful as an adjunct to established diagnostic testing. 
 
 
 
 
 
TABLES/FIGURES 
Table 1. Descriptive Statistics for HGD/Invasive Outcomes (HGD, PDAC, IPMN-Invasive) 
 Surgery (n=98) Surveillance (n=185) 
Benign 75 (3.6; 2.1-11.4months) 185 (47.3; 35.6-63.2months) 
HGD/Invasive 23 (5.2; 1.3-14.6months) 0 
HGD High-Grade IPMN; PDAC  Pancreatic Ductal Adenocarcinoma; N (Time to outcome determination: Median; 
Interquartile Range); Time based on time of surgery, or most recent benign follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Most Significant  Predictors of HGD/Invasive Outcome: Surgery and Surveillance 
 TP FP Sn (%) 
Sp 
(%) 
Acc 
(%) LR+ 
PPV   
(%) 
NPV 
(%) P-Value 
High Quantity DNA (18/23) (123/260) 78.3 52.7 54.8 2 12.8 96.5 0.004* 
 + KRAS (8/22) (36/235) 36.4 84.7 80.5 2 18.2 93.4 0.032* 
 +KRAS + GNAS (2/3) (1/21) 66.7 95.2 91.7 14 66.7 95.2 0.032* 
 +KRAS + HC LOH (2/20) (2/200) 10.0 99.0 90.9 10 50.0 91.7 0.042* 
 +HC LOH (3/20) (2/200) 15.0 99.0 91.4 15 60.0 92.1 0.006* 
High Quality DNA (11/23) (78/260) 47.8 70.0 68.2 2 12.4 93.8 0.078 
 +KRAS (5/22) (21/235) 22.7 91.1 85.2 3 19.2 92.6 0.056 
 +KRAS + GNAS (2/3) (1/21) 66.7 95.2 91.7 14 66.7 95.2 0.032* 
 +KRAS + HC LOH (2/20) (0/200) 10.0 100.0 91.8  -  100.0 91.7 0.008* 
 +HC LOH (3/20) (0/200) 15.0 100.0 92.3  -  100.0 92.2 0.001* 
 +LOH (3/20) (7/200) 15.0 96.5 89.1 4 30.0 91.9 0.051 
High Risk DNA (10/23) (60/260) 43.5 76.9 74.2 2 14.3 93.9 0.030* 
 +KRAS (4/22) (15/235) 18.2 93.6 87.2 3 21.1 92.4 0.066 
 +KRAS + GNAS (2/3) (1/21) 66.7 95.2 91.7 14 66.7 95.2 0.032* 
 +HC LOH (2/20) (0/200) 10.0 100.0 91.8  -  100.0 91.7 0.008* 
HC LOH (4/20) (4/200) 20.0 98.0 90.9 10 50.0 92.5 0.003* 
 + KRAS (3/20) (4/200) 15.0 98.0 90.5 7 42.9 92.0 0.018* 
 + HC KRAS (3/20) (3/200) 15.0 98.5 90.9 10 50.0 92.1 0.011* 
          
TP True Positive (n-positive/n-tested in malignant group) ; FP False Positive (n-positive/n-tested in benign group); Sn 
Sensitivity; Sp Specificity; Acc Accuracy; LR+ Positive Likelihood Ratio; PPV Positive Predictive Value; NPV Negative Predictive 
Value; HC LOH High Clonality Loss of Heterozygosity of Tumor Suppressor Genes; HC KRAS High Clonality KRAS Mutation; 
High Quantity+ Quality DNA = High Risk DNA; *denotes P<0.05 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Most Significant  Predictors of HGD/Invasive Outcome: Surgery Only 
  TP FP Sn (%) 
Sp   
(%) 
Acc 
(%) LR+ 
PPV 
(%) 
NPV 
(%) P-Value 
High Quantity DNA (18/23) (38/75) 78.3 49.3 56.1 2 32.1 88.1 0.019* 
 +KRAS + GNAS (2/3) (1/15) 66.7 93.3 88.9 10 66.7 93.3 0.056 
High Quality DNA (11/23) (17/75) 47.8 77.3 70.4 2 39.3 82.9 0.019* 
 +KRAS +GNAS (2/3) (1/15) 66.7 93.3 88.9 10 66.7 93.3 0.056 
 +KRAS +HC LOH (2/20) (0/55) 10.0 100.0 76.0  -  100.0 75.3 0.068 
 +HC LOH (3/20) (0/55) 15.0 100.0 77.3  -  100.0 76.4 0.017* 
High Risk DNA  (10/23) (14/75) 43.5 81.3 72.4 2 41.7 82.4 0.015* 
 +KRAS +GNAS (2/3) (1/15) 66.7 93.3 88.9 10 66.7 93.3 0.056 
 +HC LOH (2/20) (0/55) 10.0 100.0 76.0  -  100.0 75.3 0.068 
HC LOH (4/20) (3/55) 20.0 94.5 74.7 4 57.1 76.5 0.077 
          
TP True Positive (n-positive/n-tested in malignant group); FP False Positive (n-positive/n-tested in benign group); Sn 
Sensitivity; Sp Specificity; Acc Accuracy; LR+ Positive Likelihood Ratio; PPV Positive Predictive Value; NPV Negative Predictive 
Value; HC LOH High Clonality Loss of Heterozygosity of Tumor Suppressor Genes; High Quantity/Quality DNA = High Risk DNA; 
*denotes P<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ICG+ WF+ ICG- ICG+ WF+ ICG- ICG+ WF+ ICG- ICG+ WF+ ICG- ICG+ WF+ ICG- ICG+ WF+ ICG- ICG+ WF+ ICG-
High Quantity DNA 0.376 0.113 0.118 69.2 72.7 100.0 45.2 55.0 51.6 52.3 56.8 52.5 1.3 1.6 2.1 34.6 15.1 3.9 77.8 94.8 100.0
High Quality DNA 0.071 0.484 1.000 61.5 36.4 33.3 67.7 74.0 68.4 65.9 70.3 67.7 1.9 1.4 1.1 44.4 13.3 2.0 80.8 91.4 98.2
KRAS 0.295 0.745 1.000 58.3 45.5 33.3 60.0 62.5 63.4 59.5 60.6 62.8 1.5 1.2 0.9 41.2 13.2 1.9 75.0 90.2 97.8
GNAS 1.000 1.000  - 66.7 0.0  - 50.0 66.7 85.7 54.5 61.5 85.7 1.3 0.0  - 33.3 0.0 0.0 80.0 88.9 100.0
LOH 0.358 0.108 1.000 30.0 20.0 0.0 85.7 95.9 87.8 67.7 86.7 85.7 2.1 4.9 0.0 50.0 40.0 0.0 72.0 89.7 97.3
HC LOH 0.027 0.037 1.000 30.0 20.0 0.0 100.0 98.6 97.6 77.4 89.2 95.2  - 14.6 0.0 100.0 66.7 0.0 75.0 90.0 97.6
 +High Quality DNA 0.027 0.120  - 30.0 10.0 0.0 100.0 100.0 100.0 77.4 89.2 97.6  -  -  - 100.0 100.0  - 75.0 89.0 97.6
 +KRAS 0.097 0.037 1.000 20.0 20.0 0.0 100.0 98.6 97.6 74.2 89.2 95.2  - 14.6 0.0 100.0 66.7 0.0 74.2 90.0 97.6
 +HC KRAS 0.097 0.013 1.000 20.0 20.0 0.0 100.0 100.0 97.6 74.2 90.4 95.2  -  - 0.0 100.0 100.0 0.0 72.4 90.1 97.6
Table 4. Performance of DNA Features for Predicting HGD/Invasive Outcomes by Consensus Guidelines Subgroups
LR+ Pos i tive Likel ihood Ratio; PPV Pos i tive Predictive Va lue; NPV Negative Predictive Va lue; HC LOH  High Clonal i ty Loss  of Heterozygos i ty of Tumor Suppressor Genes ; HC KRAS High 
Clonal i ty KRAS Mutation; ICG+ (recommended for surgery based on cons ideration of a l l  consensus  guidel ines  radiographic/endoscopic cri teria ); WF+ (presence of consensus  
guidel ines  Worrisome Features  only); ICG- (not recommended for surgery based on cons ideration of a l l  consensus  guidel ines  radiographic/endoscopic cri teria )
P-value NPV (%)PPV (%)LR+Accuracy (%)Specificity (%)Sensitivity (%)
Table 1s. DNA Components Not Reaching Statistical Significance for HGD/Invasive Outcome: 
Surgery and Surveillance 
  TP FP Sn (%) 
Sp 
(%) 
Acc 
(%) LR+ 
PPV 
(%) 
NPV 
(%) 
P-
Value 
High Quantity DNA  -   -   -   -   -   -   -   -    -  
 +HC KRAS (3/22) (12/235) 13.6 94.9 87.9 3 20.0 92.2 0.126 
 +GNAS (2/3) (4/21) 66.7 81.0 79.2 4 33.3 94.4 0.143 
 +HC GNAS (1/3) (1/21) 33.3 95.2 87.5 7 50.0 95.9 0.239 
 +LOH (3/20) (12/200) 15.0 94.0 86.8 3 20.0 91.7 0.144 
 +KRAS + GNAS + LOH (1/3) (1/18) 33.3 94.4 85.7 6 50.0 89.5 0.271 
 +KRAS + LOH (1/20) (5/200) 5.0 97.5 89.1 2 16.7 91.1 0.439 
High Quality DNA -  -   -   -  -   -   -   -   -  
 +HC KRAS (2/22) (8/235) 9.1 96.6 89.1 3 20.0 91.9 0.207 
 +GNAS (2/3) (4/21) 66.7 81.0 79.2 4 33.3 94.4 0.143 
 +HC GNAS (1/3) (1/21) 33.3 95.2 87.5 7 50.0 90.9 0.239 
 +KRAS + GNAS + LOH (1/3) (1/18) 33.3 94.4 85.7 6 50.0 89.5 0.271 
 +KRAS + LOH (2/20) (4/200) 10.0 98.0 90.0 5 33.3 91.6 0.094 
High Risk DNA  -   -   -   -   -   -   -   -   -  
 +HC KRAS (3/22) (10/235) 13.6 95.7 88.7 3 23.1 92.2 0.089 
 +GNAS (2/3) (4/21) 66.7 81.0 79.2 4 33.3 94.4 0.143 
 +HC GNAS (1/3) (1/21) 33.3 95.2 87.5 7 50.0 90.9 0.239 
 +LOH (2/20) (6/200) 10.0 97.0 89.1 3 25.0 91.5 0.158 
 +KRAS + GNAS + LOH (1/3) (1/18) 33.3 94.4 85.7 6 50.0 89.5 0.271 
 +KRAS + LOH (1/20) (3/200) 5.0 98.5 90.0 3 25.0 91.2 0.319 
 +KRAS + HC LOH (1/20) (0/200) 5.0 100.0 91.4  -  100.0 91.3 0.091 
KRAS (11/22) (87/235) 50.0 63.0 61.9 1 11.2 93.1 0.231 
 +GNAS (2/3) (4/21) 66.7 81.0 79.2 4 33.3 94.4 0.143 
 +LOH (3/20) (12/200) 15.0 94.0 86.8 3 20.0 91.7 0.144 
HC KRAS (5/22) (33/235) 22.7 86.0 80.5 2 13.2 92.2 0.340 
 +HC GNAS (1/3) (1/21) 33.3 95.2 87.5 7 50.0 90.9 0.239 
GNAS (2/3) (6/21) 66.7 71.4 70.8 2 25.0 93.8 0.249 
HC GNAS (1/3) (2/21) 33.3 90.5 83.3 4 33.3 90.5 0.343 
LOH (4/20) (20/200) 20.0 90.0 83.6 2 16.7 91.8 0.247 
CEA >1000 (7/15) (58/209) 46.7 72.2 70.5 2 10.8 95.0 0.143 
          
TP True Positive (n-positive/n-tested in malignant group); FP False Positive (n-positive/n-tested in benign group); Sn 
Sensitivity; Sp Specificity; Acc Accuracy; LR+ Positive Likelihood Ratio; PPV Positive Predictive Value; NPV Negative Predictive 
Value; HC LOH High Clonality Loss of Heterozygosity of Tumor Suppressor Genes; HC KRAS High Clonality KRAS Mutation; HC 
GNAS High Clonality GNAS Mutation; High Quantity + Quality DNA = High Risk DNA 
 
 
 
Table 2s. DNA Components Not Reaching Statistical Significance for HGD/Invasive Outcome: 
Surgery Only 
  TP FP Sn (%) 
Sp    
(%) 
Acc 
(%) LR+ 
PPV 
(%) 
NPV 
(%) 
P-
Value 
High Quantity DNA  -   -   -   -   -   -   -   -  - 
 +KRAS  (8/22) (16/67) 36.4 76.1 66.3 2 33.3 78.5 0.252 
 +HC KRAS (3/22) (6/67) 13.6 91.0 71.9 2 33.3 76.3 0.684 
 +GNAS (2/3) (4/15) 66.7 73.3 72.2 3 33.3 91.7 0.245 
 +HC GNAS (1/3) (1/15) 33.3 93.3 83.3 5 50.0 87.5 0.314 
 +LOH  (3/20) (6/55) 15.0 89.1 69.3 1 33.3 74.2 0.693 
 +HC LOH (3/20) (2/55) 15.0 96.4 74.7 4 60.0 75.7 0.114 
 +KRAS + GNAS + LOH (1/3) (1/12) 33.3 91.7 80.0 4 50.0 84.6 0.371 
 +KRAS + LOH (1/20) (3/55) 5.0 94.5 70.7 1 25.0 73.2 1 
 +KRAS + HC LOH (2/20) (2/55) 10.0 96.4 73.3 3 50.0 74.7 0.288 
High Quality DNA  -   -   -   -   -   -   -   -  - 
 +KRAS (5/22) (6/67) 22.7 91.0 74.2 3 45.5 78.2 0.131 
 +HC KRAS (2/22) (2/67) 9.1 97.0 75.3 3 50.0 76.5 0.254 
 +GNAS (2/3) (4/15) 66.7 73.3 72.2 3 33.3 91.7 0.245 
 +HC GNAS (1/3) (1/15) 33.3 93.3 83.3 5 50.0 87.5 0.314 
 +LOH (3/20) (3/55) 15.0 94.5 73.3 3 50.0 75.4 0.333 
 +KRAS + GNAS + LOH (1/3) (1/12) 33.3 91.7 80.0 4 50.0 84.6 0.371 
 +KRAS + LOH (2/20) (3/55) 10.0 94.5 72.0 2 40.0 74.3 0.605 
High Risk DNA  -   -   -   -   -   -   -   -  - 
 +KRAS (4/22) (6/67) 18.2 91.0 73.0 2 40.0 77.2 0.255 
 +HC KRAS (3/22) (6/67) 13.6 91.0 71.9 2 33.3 76.3 0.684 
 +GNAS (2/3) (4/15) 66.7 73.3 72.2 3 33.3 91.7 0.245 
 +HC GNAS (1/3) (1/15) 33.3 93.3 83.3 5 50.0 87.5 0.314 
 +LOH (2/20) (3/55) 10.0 94.5 72.0 2 40.0 74.3 0.605 
 +KRAS + GNAS + LOH (1/3) (1/15) 33.3 91.7 80.0 4 50.0 84.6 0.371 
 +KRAS + LOH (1/20) (3/55) 5.0 94.5 70.7 1 25.0 73.2 1 
 +KRAS + HC LOH (1/20) (0/55) 5.0 100.0 74.7  -  100.0 74.3 0.267 
KRAS (11/22) (34/67) 50.0 49.3 49.4 1 24.4 75.0 0.952 
 +GNAS (2/3) (4/15) 66.7 73.3 72.2 3 33.3 91.7 0.245 
 +LOH (3/20) (7/55) 15.0 87.3 68.0 1 30.0 73.9 1 
 +HC LOH (3/20) (3/55) 15.0 94.5 73.3 3 50.0 75.4 0.333 
HC KRAS (5/22) (16/67) 22.7 76.1 62.9 1 23.8 75.0 0.912 
 +HC GNAS (1/3) (1/15) 33.3 93.3 83.3 5 50.0 87.5 0.314 
 +HC LOH (3/20) (2/55) 15.0 96.4 74.7 4 60.0 75.7 0.114 
GNAS (2/3) (6/15) 66.7 60.0 61.1 2 25.0 90.0 0.559 
HC GNAS (1/3) (2/15) 33.3 86.7 77.8 3 33.3 86.7 0.442 
LOH (4/20) (10/55) 20.0 81.8 65.3 1 28.6 73.8 1 
CEA > 1000 (7/15) (22/62) 46.7 64.5 61.0 1 24.1 83.3 0.423 
          
TP True Positive (n-positive/n-tested in malignant group); FP False Positive (n-positive/n-tested in benign group); Sn 
Sensitivity; Sp Specificity; Acc Accuracy; LR+ Positive Likelihood Ratio; PPV Positive Predictive Value; NPV Negative Predictive 
Value; HC LOH High Clonality Loss of Heterozygosity of Tumor Suppressor Genes; HC KRAS High Clonality KRAS Mutation; HC 
GNAS High Clonality GNAS Mutation; High Quantity + Quality DNA = High Risk DNA  
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